Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1992 2
1993 1
1994 2
1995 1
1998 1
1999 1
2001 1
2005 1
2007 1
2008 2
2009 1
2010 9
2011 14
2012 7
2013 7
2014 5
2015 10
2016 8
2017 8
2018 8
2019 5
2020 7
2021 12
2022 24
2023 25
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23242761

142 results

Results by year

Filters applied: . Clear all
Page 1
Future treatments for hepatitis delta virus infection.
Asselah T, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, Mansouri A. Asselah T, et al. Liver Int. 2020 Feb;40 Suppl 1:54-60. doi: 10.1111/liv.14356. Liver Int. 2020. PMID: 32077603 Review.
New therapies for hepatitis delta virus infection.
Loureiro D, Castelnau C, Tout I, Boyer N, Narguet S, Menasria Benazzouz S, Louis Z, Pons-Kerjean N, Giuly N, Marcellin P, Mansouri A, Asselah T. Loureiro D, et al. Liver Int. 2021 Jun;41 Suppl 1:30-37. doi: 10.1111/liv.14838. Liver Int. 2021. PMID: 34155804 Review.
Treatment of delta hepatitis.
Gunsar F. Gunsar F. Expert Rev Anti Infect Ther. 2013 May;11(5):489-98. doi: 10.1586/eri.13.35. Expert Rev Anti Infect Ther. 2013. PMID: 23627855 Review.
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. Bazinet M, et al. Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28. Lancet Gastroenterol Hepatol. 2017. PMID: 28964701 Clinical Trial.
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C. Keskin O, et al. Clin Gastroenterol Hepatol. 2015 Dec;13(13):2342-49.e1-2. doi: 10.1016/j.cgh.2015.05.029. Epub 2015 Jun 1. Clin Gastroenterol Hepatol. 2015. PMID: 26044319 Clinical Trial.
142 results